First-in-Human Study of EOS100850 in Patients With Cancer

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: iTeos Therapeutics
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab

Criteria

For more information regarding participation in the Trial, please refer to your physician

Inclusion Criteria:

• Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Subject with histologically or cytologically confirmed advanced solid tumor for whom no standard treatment is further available.

• At least 4 weeks since any previous treatment for cancer

• Subject must consent to pretreatment and on treatment tumor biopsies

• Adequate organ and marrow function

Exclusion Criteria:

• Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted

• Participants with second/other active cancers requiring current treatment

• Uncontrolled/significant heart disease

• Known History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

• Active/uncontrolled autoimmune disease

• Active infection

Other protocol defined inclusion/exclusion criteria could apply